Cost-Effectiveness Analysis of Panitumumab Plus Mfolfox6 Versus Bevacizumab Plus Mfolfox6 for First-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
Value Health
; 17(7): A632, 2014 Nov.
Article
in En
| MEDLINE
| ID: mdl-27202247
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Health_economic_evaluation
Language:
En
Journal:
Value Health
Journal subject:
FARMACOLOGIA
Year:
2014
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Estados Unidos